Dare Bioscience (formerly Cerulean Pharma) is a clinical-stage oncology-focused company developing nanoparticle-drug conjugates, is committed to improving treatment for people living with cancer. The Company applies Dynamic Tumor Targeting Platform to create a growing portfolio of nanoparticle-drug conjugate designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations.